Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525099 | 0.87 | ESR1 (0.36) | — | |
| SCHEMBL7532232 | 0.86 | PDK1 (0.40) | PTGDR2PDK1PDK2PDK3PDK4 | |
| SCHEMBL7528877 | 0.85 | PDK1 (0.39) | PTGDR2PDK1PDK2PDK3PDK4 | |
| SCHEMBL7530828 | 0.82 | MEN1 (0.39) | PTGDR2 | |
| Trifluoroacetic Acid SCHEMBL7529917 | 0.76 | AOC3 (0.52) | PTGDR2PDK1PDK2PDK3PDK4 | |
| SCHEMBL6421441 | 0.74 | FKBP1A (0.37) | PTGDR2PDK1PDK2PDK3PDK4 | |
| SCHEMBL29906748 | 0.72 | PARP1 (0.49) | PARP1 | |
| SCHEMBL11474322 | 0.71 | SMN1; SMN2 (0.41) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL7527042 | 0.70 | KMT2A (0.39) | — | |
| SCHEMBL7530149 | 0.69 | P2RX7 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | BIOVITRUM AB (SE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002038153-A1 | NEW USE OF 4, 5, 6, 7-TETRAHYDROIMIDAZO-[4,5-C]PYRIDINE DERIVATIVES | BIOVITRUM AB (SE) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | AOC3, AOC2, AOC1 | PTGDR2 887/4885PDK1 2180/4885PDK2 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.